{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:14:02Z","timestamp":1791645242928,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,26]]},"DOI":"10.7759\/cureus.102358","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:47:34Z","timestamp":1769496454000},"source":"Crossref","is-referenced-by-count":2,"title":["Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes"],"prefix":"10.7759","author":[{"given":"Mainak","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S167-80. 10.2337\/dc25-S008","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede HJ","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJ, et al.. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023, 108:2447-69. 10.1210\/clinem\/dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian A","year":"2019","unstructured":"Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019, 8:156-64. 10.1007\/s13679-019-00335-3","journal-title":"Curr Obes Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg A","year":"2024","unstructured":"Goldberg A, Graca S, Liu J, et al.. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024, 25:e13704. 10.1111\/obr.13704","journal-title":"Obes Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15277\/bjd.2016.092","article-title":"Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes","volume":"16","author":"Jayasinghe KNU","year":"2016","unstructured":"Jayasinghe KNU, Greener VJ, Feher MD. Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes. Br J Diabetes. 2016, 16:138. 10.15277\/bjd.2016.092","journal-title":"Br J Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch KE","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2021, 106:3019-33. 10.1210\/clinem\/dgab408","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065714","article-title":"Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes","volume":"24","author":"Reppo I","year":"2023","unstructured":"Reppo I, Jakobson M, Volke V. Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes. Int J Mol Sci. 2023, 24:5714. 10.3390\/ijms24065714","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/REP-24-0197","article-title":"The effect of chronic inflammation on female fertility","volume":"169","author":"Ameho S","year":"2025","unstructured":"Ameho S, Klutstein M. The effect of chronic inflammation on female fertility. Reproduction. 2025, 169:240197. 10.1530\/REP-24-0197","journal-title":"Reproduction"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15092","article-title":"Semaglutide and pregnancy","volume":"163","author":"Skov K","year":"2023","unstructured":"Skov K, Mandic IN, Nyborg KM. Semaglutide and pregnancy. Int J Gynaecol Obstet. 2023, 163:699-700. 10.1002\/ijgo.15092","journal-title":"Int J Gynaecol Obstet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller DR","year":"2023","unstructured":"Muller DR, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023, 14:1215356. 10.3389\/fendo.2023.1215356","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.05.154","article-title":"Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists","volume":"122","author":"Goldberg AS","year":"2024","unstructured":"Goldberg AS, Boots CE. Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists. Fertil Steril. 2024, 122:211-18. 10.1016\/j.fertnstert.2024.05.154","journal-title":"Fertil Steril"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta CE","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, et al.. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024, 184:144-52. 10.1001\/jamainternmed.2023.6663","journal-title":"JAMA Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456209-combined-glucagon-like-peptide-1-receptor-agonist-glp-1ra-and-sodium-glucose-cotransporter-2-inhibitor-sglt2i-therapy-to-restore-fertility-in-patients-with-obesity-polycystic-ovary-syndrome-and-incident-type-2-diabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:47:37Z","timestamp":1769496457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456209-combined-glucagon-like-peptide-1-receptor-agonist-glp-1ra-and-sodium-glucose-cotransporter-2-inhibitor-sglt2i-therapy-to-restore-fertility-in-patients-with-obesity-polycystic-ovary-syndrome-and-incident-type-2-diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.102358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}